Latest Articles
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer - OncLive
Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer OncLive
Published: Jan. 27, 2025, 8:21 p.m.
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer - Indian Pharma Post
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer Indian Pharma Post
Published: Jan. 21, 2025, 4:36 a.m.
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer «Кавказ Пост» - новости Северного Кавказа и Закавказья
Published: Jan. 12, 2025, 2:45 a.m.
Multiple Subcutaneous Metastases in Endometrial Cancer Treated With Systemic Chemotherapy: A Case Report and Review of the Literature - Cureus
Multiple Subcutaneous Metastases in Endometrial Cancer Treated With Systemic Chemotherapy: A Case Report and Review of the Literature Cureus
Published: Jan. 5, 2025, 6:05 a.m.
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today
Published: Dec. 18, 2024, 8:16 p.m.
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer - Medpage Today
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer Medpage Today
Published: Dec. 18, 2024, 3:27 p.m.
Chemotherapy Combinations and the Phase 3 DUO-E Trial - Cancer Network
Chemotherapy Combinations and the Phase 3 DUO-E Trial Cancer Network
Published: Oct. 24, 2024, 6:32 p.m.
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!